Hamdan Award for Medical Research Excellence in osteoporosis awarded to John A. Kanis

December 20, 2010

Professor John A. Kanis is the winner of the 2010 Hamdan Award for Medical Research Excellence in the field of osteoporosis. The prestigious Award honours his outstanding contribution to the development and validation of a widely used fracture risk assessment tool (WHO Fracture Risk Assessment Tool, or FRAX®).

The Hamdan Awards for Medical Research Excellence were presented in Dubai on December 13, 2010 by His Highness Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance and Industry, U.A.E., President of the Dubai Department of Health and Medical Services and Patron of the Award for Medical Sciences. The annual Awards pay tribute to three distinguished researchers who have made an enormous global impact through innovative research and novel advances in their respective fields.

Prof. John A. Kanis is currently the Emeritus Professor in Human Metabolism and Clinical Biochemistry and the Director of the WHO Collaborating Centre for Metabolic Bone Diseases, University in Sheffield, UK. Prof. Kanis' research interests are largely related to disorders of skeletal metabolism including osteoporosis, Paget's disease of bone, hyperparathyroidism, renal osteodystrophy and neoplasia affecting the skeleton. He has also made a number of national and international contributions to guideline development, health technology assessment, epidemiology and health economics. Prof. Kanis is President of the International Osteoporosis Foundation and WHO Advisor on Osteoporosis, among other honorary positions. He is Co Editor-in-Chief of Osteoporosis International, serves on the editorial board of several journals and is the author of more than 800 papers, chapters and books on bone disease and metabolism. His current major interest is in the development of risk assessment algorithms and the formulation of practice guidelines in many regions of the world.
-end-
About IOF

The International Osteoporosis Foundation (IOF) is a non-profit, nongovernmental organization dedicated to the worldwide fight against osteoporosis, the disease known as "the silent epidemic". IOF's members - committees of scientific researchers, patient, medical and research societies and industry representatives from around the world - share a common vision of a world without osteoporotic fractures. IOF now represents 196 societies in 92 locations around the world. http://www.iofbonehealth.org

International Osteoporosis Foundation

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.